Spectrum Pharmaceuticals, Inc. (SPPI)
Spectrum Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $1.02, down 0.49% on the session, giving a market capitalisation of $210.4M. On trailing twelve-month figures it carries a trailing P/E of -2.38, a net margin of -772.2%. Its beta of 2.14 implies it has historically moved more than the broad market.
Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Spectrum Pharmaceuticals, Inc. is most often compared with the following Healthcare names: